MedPath

Lipogems Completes Patient Enrollment in Pivotal FDA Trial for Knee Osteoarthritis Treatment

• Lipogems has completed enrollment of 173 patients across 16 U.S. sites in the ARISE II clinical trial, evaluating MicroFat injections for knee osteoarthritis treatment.

• The double-blinded, randomized controlled trial will assess pain reduction and functional improvement at 6 months post-injection, with results expected in late 2025.

• The company is pursuing a modular Premarket Approval Application (PMA) with the FDA, aiming to secure specific indication for knee OA and expand treatment accessibility through reimbursement.

Lipogems has reached a significant milestone in its pursuit of expanding treatment options for knee osteoarthritis, announcing the completion of patient enrollment in its ARISE II U.S. FDA IDE Study. The trial, which recruited 173 participants across 16 prestigious U.S. medical centers in just 9 months, aims to evaluate the efficacy and safety of MicroFat injections compared to saline controls.
The double-blinded, randomized controlled study represents the company's largest clinical trial to date, focusing on measuring improvements in pain and function at 6 months following treatment. This research builds upon the existing FDA clearance of the Lipogems device, which has been approved for orthopaedic and arthroscopic surgery applications in lipoaspirate tissue processing for the past decade.

Clinical Significance and Market Need

"With an aging population and more individuals at risk, we are excited to provide Lipogems as a treatment option for patients that are not ready or do not qualify for a knee replacement," stated Dr. Martin Roche, Director of Arthroplasty and Robotics at Hospital for Special Surgery. "We are confident these studies will prove that Lipogems will not only help improve pain and function but also positively impact the patient's quality of life so they can enjoy their families, sports, and hobbies."

Regulatory Strategy and Market Access

The ARISE I and II studies form part of Lipogems' comprehensive strategy to secure a specific indication for knee osteoarthritis treatment. Carl Llewellyn, Chief Executive Officer of Lipogems USA, emphasized the company's commitment to expanding treatment accessibility: "As a responsible company, the goal of these studies is to prove the efficacy of Lipogems for this patient population and ultimately apply and obtain reimbursement for this indication."
The company has already initiated the modular Premarket Approval Application (PMA) process following FDA confirmation, marking a crucial step toward potential commercialization. This regulatory pathway could significantly impact treatment options for patients who have experienced limited relief from conservative treatments but are not yet candidates for knee replacement surgery.

Technology Platform and Global Presence

Lipogems' proprietary technology involves closed-loop processing and transfer of lipoaspirate tissue, offering a novel approach to orthopedic treatment. The company maintains a strong international presence, with its products available in 29 countries, demonstrating its commitment to global healthcare innovation and patient care.
The anticipated release of the ARISE II trial results in late 2025 could potentially reshape the treatment landscape for knee osteoarthritis, offering a new option in the continuum of care between conservative management and joint replacement surgery.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Pivotal Trial of Novel Device for Post-Prostatectomy Incontinence Treatment

Levee Medical receives FDA approval to initiate ARID II, a multicenter randomized controlled trial evaluating the Voro Urologic Scaffold for treating stress urinary incontinence after prostate surgery.
Johns Hopkins' Dr. Arvin K. George, a prominent prostate cancer expert, will lead the pivotal study as national principal investigator to assess the device's safety and effectiveness.

Zydus' Usnoflast Receives FDA Orphan Drug Designation and Phase 2b Trial Approval for ALS Treatment

The FDA has granted Orphan Drug Designation to Zydus' Usnoflast for treating amyotrophic lateral sclerosis (ALS), a rare neurodegenerative disease.
A Phase 2b clinical trial of Usnoflast in ALS patients has been approved by the FDA, with Prof. Merit Cudkowicz as the principal investigator.

SQ Innovation's Lasix ONYU Receives Tentative FDA Approval for Congestive Heart Failure Treatment

SQ Innovation's Lasix ONYU, a combination of furosemide and an on-body device, receives tentative FDA approval for treating fluid overload in congestive heart failure.
The device, developed with Gerresheimer, allows precise, controlled drug administration and is designed for patient comfort and environmental sustainability.

Elicio Therapeutics Completes Enrollment in Phase 2 Trial of ELI-002 for mKRAS-Driven Pancreatic Cancer

Elicio Therapeutics has completed enrollment in its Phase 2 AMPLIFY-7P study, evaluating ELI-002 7P in patients with mutant KRAS-driven pancreatic cancer at high risk of relapse.
The AMPLIFY-7P study enrolled 135 patients, randomizing them to receive ELI-002 7P or standard of care observation following surgery and chemotherapy.

Phaxiam Therapeutics' Phage Therapy Receives FDA Clearance for Phase II PJI Trial

Phaxiam Therapeutics received FDA clearance for its Phase II GLORIA study, evaluating phage therapy for Staphylococcus aureus-related Prosthetic Joint Infections (PJI).
The GLORIA study is a multicenter, randomized, placebo-controlled trial assessing the efficacy of Phaxiam's anti-S. aureus phages in combination with antibiotics for PJI treatment.

FDA Approves R3 Vascular's IDE for ELITE-BTK Trial of Magnitude Scaffold in PAD

R3 Vascular received FDA IDE approval to begin the ELITE-BTK pivotal trial, evaluating the Magnitude drug-eluting bioresorbable scaffold for below-the-knee PAD.
The Magnitude scaffold, made from a unique polylactic acid polymer and coated with sirolimus, aims to improve outcomes in chronic limb-threatening ischemia (CLTI) patients.

Philips Initiates U.S. Clinical Trial for Integrated Atherectomy and Lithotripsy System in Peripheral Artery Disease

Philips has enrolled the first patient in a U.S. clinical trial evaluating its novel single-device system for treating peripheral artery disease (PAD).
The THOR trial is a prospective, single-arm, multicenter study that will enroll up to 155 patients to assess the safety and effectiveness of the integrated system.

Endospan Completes Enrollment in TRIOMPHE Trial for NEXUS Aortic Arch Stent Graft

Endospan has concluded enrollment in the primary arm of the TRIOMPHE study, evaluating the NEXUS stent graft for aortic arch disease treatment.
The NEXUS device, already CE marked in Europe, aims to provide a less invasive, off-the-shelf solution for complex aortic arch pathologies.

BioAegis Therapeutics Initiates Phase 2 Trial of Gelsolin for Acute Respiratory Distress Syndrome

BioAegis Therapeutics has commenced a Phase 2 clinical trial evaluating recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS.
The study aims to assess the efficacy and safety of rhu-pGSN in 600 patients across multiple sites in the US, Canada, the UK, and the EU.

Acasti Completes Enrollment in Phase 3 STRIVE-ON Trial of GTX-104 for aSAH

Acasti Pharma has completed patient enrollment in its Phase 3 STRIVE-ON trial evaluating GTX-104 for aneurysmal subarachnoid hemorrhage (aSAH).
The STRIVE-ON trial is comparing intravenous GTX-104 to oral nimodipine in 100 patients hospitalized with aSAH across 25 U.S. hospitals.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy